William Blair Predicts Lower Earnings for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities research analysts at William Blair lowered their Q2 2025 earnings estimates for shares of Krystal Biotech in a report released on Monday, July 14th. William Blair analyst S. Corwin now forecasts that the company will post earnings of $1.12 per share for the quarter, down from their prior estimate of $1.36. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s FY2026 earnings at $8.83 EPS.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The business had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million.

KRYS has been the topic of several other reports. Chardan Capital reissued a “buy” rating and issued a $219.00 target price on shares of Krystal Biotech in a report on Wednesday, May 7th. Guggenheim dropped their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. HC Wainwright restated a “buy” rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Tuesday, June 24th. Finally, Citigroup reaffirmed a “neutral” rating and issued a $176.00 target price (up from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $213.75.

Krystal Biotech Stock Up 1.6%

Krystal Biotech stock opened at $150.08 on Wednesday. The company has a market capitalization of $4.34 billion, a P/E ratio of 36.08 and a beta of 0.67. The stock’s 50 day moving average is $136.02 and its 200 day moving average is $156.06. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $219.34.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the business’s stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the sale, the insider directly owned 1,508,056 shares in the company, valued at approximately $226,208,400. The trade was a 0.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 49,800 shares of company stock valued at $7,487,943 in the last three months. Insiders own 13.70% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors and hedge funds have recently modified their holdings of KRYS. State of Alaska Department of Revenue lifted its holdings in Krystal Biotech by 7.9% in the second quarter. State of Alaska Department of Revenue now owns 15,130 shares of the company’s stock valued at $2,079,000 after acquiring an additional 1,106 shares during the period. Perigon Wealth Management LLC boosted its holdings in shares of Krystal Biotech by 4.8% in the second quarter. Perigon Wealth Management LLC now owns 8,898 shares of the company’s stock worth $1,223,000 after buying an additional 407 shares during the last quarter. Financiere des Professionnels Fonds d investissement inc. purchased a new position in shares of Krystal Biotech in the second quarter worth approximately $162,000. Parallel Advisors LLC grew its position in Krystal Biotech by 7.6% during the second quarter. Parallel Advisors LLC now owns 1,863 shares of the company’s stock valued at $256,000 after buying an additional 132 shares during the period. Finally, Strs Ohio purchased a new stake in Krystal Biotech during the first quarter valued at approximately $1,244,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).